medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-5-42-46medsovet-2350Research ArticleИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦАISHEMIC HEART DISEASEПолиморфизм гена β1-адренорецептора, постинфарктное ремоделирование миокарда и сердечно-сосудистый риск: есть ли взаимосвязь?The gene polymorphism of beta1-adrenoreceptor, postinfarction myocardial remodeling and cardiovascular risk: is there any correlation?ЯкушинС. С.YakushinS. S.

д.м.н., профессор

MD, Prof.

СолодунМ. В.SolodunM. V.

к.м.н.

PhD in medicine

Рязанский государственный медицинский университет им. акад. И.П. ПавловаРоссияRyazan State Medical UniversityRussian Federation201810042018054246Copyright © Якушин С.С., Солодун М.В., 20182018Якушин С.С., Солодун М.В.Yakushin S.S., Solodun M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2350

В ходе исследования изучено влияние полиморфизмов Ser49Gly и Arg389Gly гена ADRB1 на процесс постинфарктного ремоделирования миокарда и годовой прогноз у пациентов, перенесших инфаркт миокарда с подъемом сегмента ST (ИМпST). Установлено, что полиморфизмы Ser49Gly и Arg389Gly гена ADRB1 не оказывают влияния на процесс ремоделирования миокарда у пациентов, перенесших ИМпST. Аллель Ser49 ассоциирован с большей частотой возникновения острых коронарных событий, таких как смерть от сердечно-сосудистых причин, повторный нефатальный инфаркт миокарда, незапланированная реваскуляризация коронарного русла, госпитализация по поводу прогрессирующей стенокардии в течение года после перенесенного ИМпST. Аллель Gly49 и генотип Gly49Gly ассоциированы с благоприятным течением годового постинфарктного периода. Полиморфизм Arg389Gly гена ADRB1 не влияет на годовой прогноз после перенесенного ИМпST.

 

The influence of gene polymorphisms ADRB1 (Ser49Gly), ADRB1 (Arg389Gly) on myocardial remodeling and 12-month prognosis of patients with ST-segment elevation myocardial infarction (STEMI) was studied. The gene polymorphisms ADRB1 (Ser49Gly) and ADRB1 (Arg389Gly) does not affect myocardial remodeling. Ser49 allele is associated with a greater incidence of acute coronary events, such as death from cardiovascular causes, repeated non-fatal myocardial infarction, unplanned coronary revascularization, hospitalization for progressive angina pectoris within a year after STEMI. The Gly49 allele and the Gly49Gly genotype are associated with a favorable prognosis within a year after STEMI. The gene polymorphism ADRB1 (Arg389Gly) does not affect the prognosis after STEMI.

 

полиморфизм геновпрогноз после инфаркта миокардаремоделирование миокардаgene polymorphismthe prognosis after myocardial infarctionmyocardial remodelingReferencesЯкушин С.С., Филиппов Е.В. Основные направ-ления первичной профилактики сердечно-сосудистых заболеваний. Наука молодых (Eruditio Juvenium), 2014, 4: 55–68Yakushin SS, Filippov EV. Strategic directions for the primary prevention of cardiovascular diseases. Nauka Molodykh (Eruditio Juvenium), 2014, 4: 55–68.Никулина Н.Н., Якушин С.С. Современные аспекты формулировки диагноза и статистического учета инфаркта миокарда. Кардиология, 2016, 56 (9): 60–66.Nikulina NN, Yakushin SS. Modern aspects of the diagnosis formulation and statistical recording of myocardial infarction. Kardiologiya, 2016, 56 (9): 60–66.Беллил С., Якушин С.С., Аксентьев С.Б., Юневич Д.С. Сравнительный прогноз у больных пожилого и старческого возраста с перенесенным инфарктом миокарда с подъемом сегмента ST в течение 12 месяцев наблюдения в зависимости от различных схем реперфузионной терапии. Российский медико-биологический вестник им. академика И.П. Павлова, 2015, 1: 90–94.Bellil S, Yakushin SS, Aksentyev SB, Yunevich DS. Comparative prognosis in elderly and senile patients who undergone myocardial infarction with ST-segment elevation within 12-month follow-up period depending on different reperfusion therapy regimens. Rossiyskiy Mediko-biologicheskiy Vestnik Im. Akademika I.P. Pavlova, 2015, 1: 90–94Pacanowski AM, Johnson JA. ADRB1 Gene Summary. Pharmacological reviews, 2007, 59 (1): 2–4.Pacanowski AM, Johnson JA. ADRB1 Gene Summary. Pharmacological reviews, 2007, 59 (1): 2–4.Muszkat M, Stein CM. Pharmacogenetics and res ponse to beta–adrenergic receptor antagonists in heart failure. Clin Pharmacol Ther, 2005, 77 (3): 123–126.Muszkat M, Stein CM. Pharmacogenetics and res ponse to beta–adrenergic receptor antagonists in heart failure. Clin Pharmacol Ther, 2005, 77 (3): 123–126.Солодун М.В. Фармакотерапия при инфаркте миокарда: вклад генетических факторов. Российский кардиологический журнал, 2016, 3 (131): 110–115Solodun MV. Pharmacotherapy for myocardial infarction: the contribution of genetic factors. Rossiyskiy Kardiologicheskiy Zhurnal, 2016, 3 (131): 110-115.Akhter SA, D’Souza KM, Petrashevskaya NN, Mialet-Perez J, Liggett SB. Myocardial beta-1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am J Physiol Heart Circ Physiol, 2006, 290: 1427–1432.Akhter SA, D’Souza KM, Petrashevskaya NN, Mialet-Perez J, Liggett SB. Myocardial beta-1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am J Physiol Heart Circ Physiol, 2006, 290: 1427–1432.Hakalahti AE, Tapanainen JM, Junttila JM, Kaikko nen KS, Huikuri HV, Petäjä-Repo UE. Association of the beta-1 adrenergic receptor carboxyl terminal variants with left ventricular hypertrophy among diabetic and non-diabetic survivors of acute myocardial infarction. Cardiovascular Diabetology, 2010, 9 (42): 1–7.Hakalahti AE, Tapanainen JM, Junttila JM, Kaikko nen KS, Huikuri HV, Petäjä-Repo UE. Association of the beta-1 adrenergic receptor carboxyl terminal variants with left ventricular hypertrophy among diabetic and non-diabetic survivors of acute myocardial infarction. Cardiovascular Diabetology, 2010, 9 (42): 1–7.Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A. et al. Вeta1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med, 2003, 9: 1300–1305.Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A. et al. Вeta1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med, 2003, 9: 1300–1305.McLean RC, Hirsch GA, Becker LC, Kasch-Semenza L, Gerstenblith G, Schulman SP. Polymorphisms of the beta adrenergic receptor predict left ventricular remodeling following acute myocardial infarction. Cardiovasc Drugs Ther., 2011,25 (3): 251–258.McLean RC, Hirsch GA, Becker LC, Kasch-Semenza L, Gerstenblith G, Schulman SP. Polymorphisms of the beta adrenergic receptor predict left ventricular remodeling following acute myocardial infarction. Cardiovasc Drugs Ther., 2011,25 (3): 251–258.Terra Steven G, Pauly Daniel F, Lee Craig R, Patterson J Herbert, Adams Kirkwood F, Schofield Richard S et al. Вeta-аdrenergic receptor polymorphisms and responses during titration of metoprolol controlled release / extended release in heart failure. Clin Pharmacol Ther, 2005, 77 (3): 127–137.Terra Steven G, Pauly Daniel F, Lee Craig R, Patterson J Herbert, Adams Kirkwood F, Schofield Richard S et al. Вeta-аdrenergic receptor polymorphisms and responses during titration of metoprolol controlled release / extended release in heart failure. Clin Pharmacol Ther, 2005, 77 (3): 127–137.Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arhythmogenesis, prognosis, and response to beta-blocker therapy. J Am Coll Cardiol, 2008, 52 (8): 644–651.Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arhythmogenesis, prognosis, and response to beta-blocker therapy. J Am Coll Cardiol, 2008, 52 (8): 644–651.White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R et al. An evaluation of the beta–1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT–HF sub-study, 2003, 5 (4): 463–468.White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R et al. An evaluation of the beta–1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT–HF sub-study, 2003, 5 (4): 463–468.Magnusson Y, Levin MC, Eggertsen R. Ser49Gly of beta1-adrenergic receptor is associated with effective betablocker dose in dilated cardiomyopathy. Clin Pharmaco. Ther, 2005, 78 (3): 221–231.Magnusson Y, Levin MC, Eggertsen R. Ser49Gly of beta1-adrenergic receptor is associated with effective betablocker dose in dilated cardiomyopathy. Clin Pharmaco. Ther, 2005, 78 (3): 221–231.Börjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J, 2000, 21: 1853–1858.Börjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J, 2000, 21: 1853–1858.

The authors declare that there are no conflicts of interest present.